• B.Sc and Ph.D from McGill University (Canada)

• Post-doctoral training at Harvard University 

• Executive training at the Wharton Business School of University of Pennsylvania

• Translational multidisciplanary R&D, personalized medicine applied to the clinical diagnostic, device engineering, biotechnology and pharmaceutical industries

• Molecular, cellular, developmental and computational biology, microbiology, immunology, genetics, genomics, proteomics, tissue engineering-based drug assesment using 3D microfuidic culture models

• Canadian citizen by birth
• American citizen by naturalization
• Fluent in English, French and Greek
• Enjoys skiing and ice hockey 
• Composes, performs & produces music http://petertoliasmusic.site11.com

Dr. Tolias is currently Director of the university-wide Center for Healthcare Innovation and a Professor in the Department of Chemistry, Chemical Biology and Biomedical Engineering at the Stevens Institute of Technology.  He is the recipient of over three dozen grants, contracts, awards and honors, the co-founder of several diagnostic and biotechnology companies and holds board and scientific advisory memberships on scientific journals, corporations, non-profits and universities. He was formerly the Executive Director of the Institute of Genomic Medicine, Research Director of the Autism Center and Professor of Pediatrics at the New Jersey Medical School.  Previously, he served as Worldwide Vice President of Advanced Research and Technology Assessment, at Ortho-Clinical Diagnostics - a Johnson & Johnson company - and Executive Vice President of Corporate Development at Rosetta Genomics.  Earlier in his career, he was an Associate Professor of Microbiology & Molecular Genetics at the New Jersey Medical School, an Associate Member of the NY Public Health Research Institute and earlier as an Assistant Member.

• Member, IRB Committee

• Member, Science Advisory Board, Rider University (03–present)
• Fellow, North American Academy of Arts and Sciences (01-present)
• Member, Medical Advisory Committee, Board of Trustees, Leukemia & Lymphoma Society, New Jersey Chapter (03-present)
• Member, Clinical Sciences Committee, Personalized Medicine Coalition (08-present)
• Editorial Board, Personalized Medicine (08-present)
• Editorial Board, TheScientificWorldJOURNAL (11-present)
• Founder & President, BioConsulting and Financial Sourcing Services LLC (06-present)
• Co-Founder, Chairman of the Board of Directors (09-10), Chief Scientific & Business Advisor (10-12), CGC Genetics Inc.
• Co-Founder and Chief Scientific Advisor, Sundance Diagnostics Inc. (10-present)
• Member, Scientific Advisory Board, BioSample Solutions Inc. (10-12)
• Co-Founder and Science Advisory Board Chairman, NanoMedica Inc. (01–present)
• Member, NIH Study Section Grant Review Panel, National Cancer Institute (99-03)
• Member, Scientific Advisory Board, PharmaSeq Inc. (00-02)

• New Jersey R&D Council 2007 Thomas Alva Edison Patent Award for Emerging Technologies
• Medical Research Council of Canada (MRC) Centennial Fellowship. (Ranked 4^th on list of top Canadian MRC-sponsored junior research faculty) (1990-91)
• MRC  Fellowship (1989-90)
• MRC Fellowship (1987-89)
• Ph.D conferred from McGill University with ‘Distinction’/Dean's Honors list (1987)
• Recipient of the 1987 McGill Dept. of Microbiology &  Immunology W. Yaphe Award  (top graduating Ph.D student)
• MRC Studentship (1988-87)
• Natural Sciences & Engineering Research Council of Canada (NSERC) Postgraduate Scholarship (1984-85)
• NSERC Postgraduate Scholarship (1983-84)
• Quebec Provincial FCAC Studentship (declined and accepted another) (1983-84)
• McGill University Faculty of Medicine Internal Award (declined and accepted another) (1982-83)
• NSERC Postgraduate Scholarship (1982-83)
• McGill University Graduate Faculty Summer Research Fellowship (1982)
• B.Sc conferred from McGill University with ‘Distinction’/ Dean's Honors list (1981)

Current

• Director, Bioinnovation Program, Stevens Institute of Technology
• Professor, Department of Chemistry, Chemical Biology and Biomedical Engineering Stevens Institute of Technology

Previous

• Executive Director, Institute of Genomic Medicine, New Jersey Medical School (07-12)
• Professor, Department of Pediatrics, New Jersey Medical School (07-12)
• Research Director, The Autism Center, New Jersey Medical School (08-12)
• Executive Vice President, Global Corporate Development, Rosetta Genomics Ltd. (06-07)
• Adjunct Professor, Department of Molecular Genetics, Microbiology & Immunology, Robert Wood Johnson Medical School (04-12)
• Vice President, Worldwide Advanced Research, Ortho-Clinical Diagnostics - a Johnson & Johnson company (03-06)
• Founder & Director, Center for Applied Genomics, Public Health Research Institute (00-03), Member, Board of Directors, (97-03), Associate Faculty Member (96-03), Assistant Faculty Member (91-96)
• Associate Professor, Department of Microbiology & Molecular Genetics, New Jersey Medical School, (00-03)
• Adjunct Associate Professor, Federated Department of Biological Sciences, Rutgers University Newark and New Jersey Institute of Technology (00-03)
• Visiting Scholar, Department of Biology, New York University (91–00)
• Associate, Department of Cellular & Developmental Biology, Harvard University (90-91)

Recent Invited Public Lectures

• International Conference on Genomics in the Americas, Sept 27-28, 2012, Philadelphia PA.  “Drug Selection and Assessment Based on Whole Genome Sequencing and Microfluidic 3D Culturing as a New Paradigm for Personalized Therapeutics”
• Omics Evolution Summit: Genomic, Proteomic and Metabolomic Drug Discovery, May 30-31, 2012, Boston MA.  “Microfluidic 3D Culture as a Model for Personalized Therapeutics”
•  Partnerships in Personalized Medicine for Diagnostics, July 11-12, 2011, San Mateo, CA.  “Enablement of Personalized Medicine Through Partnerships With Academic Medical Centers”
• 3^rd Annual UMDNJ Technology Symposium. Advances in Imaging and Genomics: Innovative Research Technologies to Bridge Bench to Bedside, April 12, 2011, Piscataway NJ.  “Genomic Technologies Used In Molecular Diagnostics”
• NextLevel Pharma, Commercialization Strategies and Market Access for Personalized Medicines and Companion Diagnostics, Feb. 9-10, 2011, Miami FL.  “Models of Academia/Industry Partnerships Enabling Personalized Medicine”
• CHI Co-Development of Drugs and Diagnostics, Aug 25-26, 2010, Washington DC.  “Adoption of Companion Diagnostics by Industry and Academia”
• Partnerships in Personalized Medicine for Diagnostics, Apr 12-13, 2010, San Mateo, CA.  “Biomarker Development Supporting Personalized Medicine”
• IQ Saude, March 25-26, 2010, Coimbra Portugal.  “Role of Diagnostics in Healthcare Reform”
• Biotech 2009, Nov 16-17, 2009, Philadelphia, PA. “The Evolving Role of Diagnostics in Bioscience Technology and Health Care: Perspective from an Academic Clinical Lab”

Symposium Organizer


• Organized and chaired New Jersey’s first International Symposium on personalized medicine entitled “Symposium on Human Variation:  A Driver of Personalized Medicine.”   This two-day symposium (Jan 29-30, 2009) featured lectures, panel discussions and poster presentations from 18 influential academic and industry scientists and policy makers across North America working at the forefront of translational R&D and the enablement of personalized medicine.  The audience included basic and clinical research scientists, clinicians, genetic counselors, graduate students, medical residents and postdoctoral fellows.  Professor Tolias developed the program and curriculum (9.75 CME Credits), identified and invited the speakers and sponsors and gave the introductory lecture.

Contracts:

• $284,000 (2010-2012) from CGC Genetics for clinical diagnostic services
• $240,000 (10/08-10/10) from Advaxis Inc. for microarray gene expression profiling of patients in a phase II study to determine safety, efficacy and immunogenicity of vaccination with Listeria monocytogenes expressing Human Papilloma Virus type 16E7 for the treatment of Intraepithelial Carcinoma Stage 2/3
• $650,000 (2007-12) from Saint Barnabas Healthcare System for providing genetic counseling services to three of their New Jersey Hospitals
• $194,400 (2008-10) from Genewiz Inc. for clinical diagnostic DNA sequencing services
• $240,000 (2008-12) from BioArray Solutions, a subsidiary of Immucor Inc., for development and offering of clinical blood-typing assays
• $50,000 (2008-9) from Bioscience Development Inc. for development of a mass spectrometer immunoassay to detect Lyme Disease
• $80,050, (2008-2009) from Siemens Corporate Research, Inc. to develop a PCR assay that detects a pathogenic strain of Staphylococcus aureas

Grants as Principal Investigator (PI):

• Qualifying Therapeutic Discovery Project (QTDP) grant from the US Department of the Treasury for $244,479 (10/31/10): Whole Genome Sequencing for Diagnostic Test for Suicidal Ideation
• National Institutes of Health (NIH), National Cancer Institute (NCI): $231,463 supplement to grant  #R33 CA83213 (5/2/02-8/31/03)
• New Jersey Commission on Science and Technology (NJCST) R&D excellence Program: Grant # 00-2042-007-21.  Support for the Center for Applied Genomics from 1/1/00-12/31/04.  $1,200,000
• Hyde and Watson Foundation: $50,000 (1/1/00-12/31/00)
• NIH, NCI: Grant R21/33 CA83213, $2,144,870 (09/27/99 08/31/03)
• NIH, National Human Genome Research Institute (NHGRI): Grant # R21HG01783, $320,475 (4/15/98 -3/31/00)
• Markey Charitable Trust-Sponsored PHRI New Initiative Program: $38,000 (10/1/96-9/30/97)
• National Science Foundation, (NSF) Developmental Mechanisms Program: Grant# IBN-9418722, $355,000 (3/1/95-2/28/98)
• NSF Developmental Mechanisms Program: Grant# DCB-9117180, $300,000 (1/1/92-12/31/94)

 Grants as Co-PI:

• The Healthcare Foundation of New Jersey:  Application of MSIA Technology and Protein Variation Testing as a means to characterize cardiac risk in African-Americans.  Total award: $160,450 (9/08-9/10) to Schwalb (PI)
• UMDNJ Office of Patents & Licensing Technology Commercialization Fund Grant Awards: Identification of Risk Alleles for Multiple Sclerosis to Vitale (PI).  Total award: $37,500 (2008)
• $300,000 subcontract from New Jersey Institute of Technology through NSF Grant #DBI-0243302 to develop SmartPin technology. Total award $634,486 (9/1/03-8/31/06) Chang (PI)
• NIH, National Heart, Lung and Blood Institute: Grant# RO1 HL68513 to Smith, (PI). Total award: $2,334,000 (9/10/01-7/31/06)
• $159,050 (01/01/02) subcontract from UMDNJ through New Jersey Commission on Higher Education, High Tech Workforce Excellence Grant for a Graduate Program in Bioinformatics.  Total award: $2,263,000 (1/1/01-12/31/03) to Welsh, (PI)
• $1,830,298 subcontract from UMDNJ-NJMS through Dept. of Defense USAMRMC Grant #DAMD17-01-1-0787, Use of DNA Microarrays to Identify Diagnostic Signature Transcriptional Profiles for Host Responses to Infectious Agents. Total award: $2,875,432 (09/29/01-10/31/03) to Ellner (PI)
• NIH, National Institute of Environmental Health Sciences (NIEHS):  Grant #RO1 ES10536 to Tyagi, (PI). Total award: $1,594,450 (9/30/99-10/01/02)
• $10,000 subcontract from Sequenom Inc. through NIH, National Institute of Allergy and Infectious Diseases (NIAID Phase I SBIR grant # R43 AI47528 to Little (PI).  Total award: $100,000 (6/1/00-11/30/00)

• T. Chang, P. Tolias (2006). Delivery of Metered Amounts of Liquid Materials.  Patent # 7,097,810